Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Summary

This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.

Timeline

Start

2018-10-17

Primary completion

2019-02-18

Completion

2019-02-18

Drugs

Indications